This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2019 Aug;54(8):466-467.

doi: 10.1097/RLI.0000000000000589.

Gadolinium Retention in the Brain: What Do We Need to Consider for Clinical Use?

Johannes T Heverhagen¹, Michael V Knopp¹

Affiliations

PMID: 31261308
DOI: 10.1097/RLI.0000000000000589

Editorial

Gadolinium Retention in the Brain: What Do We Need to Consider for Clinical Use?

Johannes T Heverhagen et al. Invest Radiol. 2019 Aug.

. 2019 Aug;54(8):466-467.

doi: 10.1097/RLI.0000000000000589.

Authors

Johannes T Heverhagen¹, Michael V Knopp¹

Affiliation

¹ Department of Radiology, The Wright Center for Innovation in Biomedical Imaging, The Ohio State University, Columbus, OH.

PMID: 31261308
DOI: 10.1097/RLI.0000000000000589

No abstract available

PubMed Disclaimer

Comment on

Gadolinium-Based MRI Contrast Agents Induce Mitochondrial Toxicity and Cell Death in Human Neurons, and Toxicity Increases With Reduced Kinetic Stability of the Agent.
Bower DV, Richter JK, von Tengg-Kobligk H, Heverhagen JT, Runge VM. Bower DV, et al. Invest Radiol. 2019 Aug;54(8):453-463. doi: 10.1097/RLI.0000000000000567. Invest Radiol. 2019. PMID: 31265439

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

Grants and funding

U24 CA180803/CA/NCI NIH HHS/United States

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wolters Kluwer